K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · SMITH & NEPHEW INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | SNN | SMITH & NEPHEW INC. | SMITH & NEPHEW, INC. | $420K | Medicare physician fee schedule and Medicare hospital outpatient rule, issues related to skin substitutes. Issues related to Medicare local coverage determinations for skin substitutes. H.R. 5768 / S. 2561, Skin Substitute Access and Payment Reform Act of 2025. H.R. 6852 Advanced Wound Care and Regenerative Medicine Access and Reform Act. Issues related to APNRM on Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. Issues related to section 899 of the One Big Beautiful Bill Act, H.R.1. Issues related to tariffs. Issues related to the USMCA trade agreement. Educate key government stakeholders on Smith+Nephew products applicable to the military and seek support for appropriations requests. |
| 2026-04-15 | SNN | SMITH & NEPHEW INC. | THE NICKLES GROUP, LLC | $60K | Issues related to disposable negative pressure wound therapy. Issues related to payment for skin substitutes wound treatments. Issues related to coding and payment rates for tympanostomy and other procedures involving pediatric medical devices. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to payments for medical devices. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitor OECD negotiations related to Pillar II global minimum tax. Monitored issues related to price transparency. Monitored issues related to tariffs. |
| 2026-01-20 | SNN | SMITH & NEPHEW INC. | SMITH & NEPHEW, INC. | $340K | Medicare physician fee schedule and Medicare hospital outpatient rule, issues related to skin substitutes. Medicare physician fee schedule issues related to pediatric tympanostomies. H.R. 1931 / S. 249, Access to Pediatric Technologies Act of 2025. H.R. 5768 / S. 2561, Skin Substitute Access and Payment Reform Act of 2025. Issues related to section 899 of the One Big Beautiful Bill Act, H.R.1. Issues related to tariffs. Educate key government stakeholders on Smith+Nephew products applicable to the military and seek support for appropriations requests. |
| 2026-01-20 | SNN | SMITH & NEPHEW INC. | THE NICKLES GROUP, LLC | $60K | Monitored issues related to tariffs. Issues related to disposable negative pressure wound therapy. Issues related to payment for skin substitutes wound treatments. Issues related to coding and payment rates for tympanostomy and other procedures involving pediatric medical devices. S. 249/H.R. 1931, Access to Pediatric Technologies Act of 2025. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to pass-through payments for medical devices. Issues related to Most Favored Nation drug pricing. Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitor OECD negotiations related to Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations. Monitored issues related to price transparency. |
| 2025-10-20 | SNN | SMITH & NEPHEW INC. | SMITH & NEPHEW, INC. | $350K | Issues related to tariffs. Educate key government stakeholders on Smith+Nephew products applicable to the military and seek support for appropriations requests. Medicare physician fee schedule, Medicare hospital outpatient rule, and Medicare Administrative Contractor policies, issues related to skin substitutes. Medicare physician fee schedule and Medicare Administrative Contractor policies, issues related to pediatric tympanostomies. H.R. 1931 / S.249, Access to Pediatric Technologies Act of 2025. S. 2561, Skin Substitute Access and Payment Reform Act of 2025. Issues related to the base erosion and anti-abuse tax. Section 899 of the One Big Beautiful Bill Act, H.R.1. Issues related to medical device sterilization and the use of ethylene oxide for sterilization under EPAs proposed regulations for the National Emission Standards for Hazardous Air Pollutants and the Federal Insecticide, Fungicide, and Rodenticide Act. |
| 2025-10-12 | SNN | SMITH & NEPHEW INC. | THE NICKLES GROUP, LLC | $60K | Issues related to disposable negative pressure wound therapy. Issues related to payment for skin substitutes wound treatments. Issues related to coding and payment rates for tympanostomy and other procedures involving pediatric medical devices. S. 249/H.R. 1931, Access to Pediatric Technologies Act of 2025. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to pass-through payments for medical devices. Monitored H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to Medicaid. Issues related to Most Favored Nation drug pricing. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitored issues related to price transparency. Monitored issues related to tariffs. |
| 2025-07-21 | SNN | SMITH & NEPHEW INC. | SMITH & NEPHEW, INC. | $370K | Medicare physician fee schedule and Medicare Administrative Contractor policies, issues related to skin substitutes. Medicare physician fee schedule and Medicare Administrative Contractor policies, issues related to pediatric tympanostomies. H.R. 1931 / S.249, Access to Pediatric Technologies Act of 2025. Issues related to the base erosion and anti-abuse tax. Section 899 of the One Big Beautiful Bill Act, H.R.1. Educated key government stakeholders on Smith+Nephew products applicable to the military and support appropriations requests. Issues related to medical device sterilization and the use of ethylene oxide for sterilization under EPAs proposed regulations for the National Emission Standards for Hazardous Air Pollutants and the Federal Insecticide, Fungicide, and Rodenticide Act. Issues related to tariffs. |
| 2025-07-17 | SNN | SMITH & NEPHEW INC. | THE NICKLES GROUP, LLC | $60K | Issues related to disposable negative pressure wound therapy. Issues related to payment for skin substitutes wound treatments. Issues related to coding and payment rates for tympanostomy and other procedures involving pediatric medical devices. S. 249/H.R. 1931, Access to Pediatric Technologies Act of 2025. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to pass-through payments for medical devices. Monitored H.R.1, One Big Beautiful Bill Act, as it relates to Medicaid. Issues related to Most Favored Nation drug pricing. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitored issues related to price transparency. Monitored issues related to tariffs. |
| 2025-04-21 | SNN | SMITH & NEPHEW INC. | SMITH & NEPHEW, INC. | $430K | Educated key government stakeholders on Smith+Nephew products applicable to the military and support appropriations requests. Medicare physician fee schedule and Medicare Administrative Contractor policies, issues related to skin substitutes. Medicare physician fee schedule and Medicare Administrative Contractor policies, issues related to pediatric tympanostomies. H.R. 1931 / S.249, Access to Pediatric Technologies Act of 2025. Issues related to the base erosion and anti-abuse tax. Issues related to the amortization of R&D expense & Issues related to the deduction of interest expense. Issues related to medical device sterilization and the use of ethylene oxide for sterilization under EPAs proposed regulations for the National Emission Standards for Hazardous Air Pollutants and the Federal Insecticide, Fungicide, and Rodenticide Act. Issues related to tariffs. |
| 2025-04-20 | SNN | SMITH & NEPHEW INC. | THE NICKLES GROUP, LLC | $60K | Issues related to disposable negative pressure wound therapy. Issues related to payment for skin substitutes wound treatments. Issues related to coding and payment rates for tympanostomy and other procedures involving pediatric medical devices. S. 249/H.R. 1931, Access to Pediatric Technologies Act of 2025. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to pass-through payments for medical devices. Monitor implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to corporate and international taxes. Issues related to the R&D credit and interest expense deduction. Monitored issues related to taxation of foreign-based multinationals. Issues related to the extension of the Tax Cut and Jobs Act provisions impacting corporations. Monitored issues related to price transparency. Monitored issues related to tariffs. |
| 2025-01-20 | SNN | SMITH & NEPHEW INC. | NVG, LLC | $50K | Issues related to the regulation of medical devices. Coverage of in-office tympanostomy. Issues related to coverage of novel pediatric devices. H.R.9157/S.5257 - Access to Pediatric Technologies Act of 2024. Issues related to coverage of skin substitutes. |